about
Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical researchAdvances in recombinant antibody manufacturingBeyond cancer treatment - a review of total lymphoid irradiation for heart and lung transplant recipients.Anti-CD3 mAbs for treatment of type 1 diabetesTherapeutic drug monitoring of immunosuppressant drugs.Production of recombinant antibodies using bacteriophages.A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).T cell tolerance induced by therapeutic antibodiesPotent antibody therapeutics by design.Pre-existing Antibody: Biotherapeutic Modality-Based Review.Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Research and development of therapeutic mAbs: An analysis based on pipeline projects.Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.Monoclonal antibodies for the treatment of severe asthma.Analysis of glycoforms on the glycosylation site and the glycans in monoclonal antibody biopharmaceuticals.Revisiting the Discovery of the αβ TCR Complex and Its Co-Receptors.Novel Biologicals for the Treatment of Allergic Diseases and Asthma.Molecular and functional analysis of monoclonal antibodies in support of biologics development.Hurdles and leaps for protein therapeutics.Precision Subtypes of T Cell-Mediated Rejection Identified by Molecular Profiles.Raman spectroscopy characterization of antibody phases in serum.Muromonab-CD3-induced neurotoxicity: report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity.Alterations in antibody subclass immune reactivity to trophoblast-derived fetal fibronectin and α2-macroglobulin in women with recurrent pregnancy loss.Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Development of Monoclonal Antibodies: The Dawn of mAb Rule.Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition
P2860
Q24289253-7C8A1052-BA75-4B5B-B181-0D597B8A974AQ26764949-A6162221-F547-44E3-A2E3-465732C99F3CQ26801075-CBF0603C-ACD4-4277-BD48-27C6F8F22D30Q28239248-7949DF87-F5A0-4237-AF44-841798F42834Q33610775-A2E19F5E-697B-4212-B648-47586F010A15Q33643027-D18593DC-901E-4611-A6D6-BA2390960D79Q33810163-84F93E33-CFCE-4477-A226-57028F84ADD8Q34828735-445D3719-D307-49F0-BDFA-E26193FC37B4Q36251293-5D456AC9-9AAD-45C8-BE95-DA06C95952B6Q36452621-3F6CAE11-B7E5-4564-A81A-AEEF71DB5440Q36653888-B7AAF50D-624D-468E-A3F8-893578EF58F2Q36767393-5FABED6E-61BB-4B1A-BEF9-28E9A78AF080Q37019872-E914068B-9062-406C-85A6-45F616629B92Q37027607-FF149C39-0110-4ABB-834B-E149FECA1935Q37332203-613BC030-8C10-42F4-9EFE-48598C86B075Q37848219-DF4AC66B-BD27-4C62-8B42-A64E3A037C01Q37972871-5F5CDAD3-A5D5-49D1-9C5D-F2195639B427Q38284910-3FD724F1-71DD-4DC3-A243-91F35690F4BAQ38950769-A78A8C00-B768-427F-8030-41F0C69207CAQ39451572-B2EB1087-23F6-4A83-87F7-3DBD25EC87FCQ39909788-59CBBE13-CE53-4889-A850-C44AEF0A333EQ40289674-F3CE3B1F-A859-48D8-80F9-DAECFD705676Q42177409-05EE0618-118C-4B8F-8A37-F497295C6895Q43815298-E9885C21-ABBC-4A2B-B576-1394175FBB94Q43890936-CF59409A-9819-4458-8C5A-685651102537Q45858720-F462FED5-686E-402D-A5DE-D8EFD0981B87Q49592680-CCFF8A84-560C-4584-8332-FF0B67E0A527Q51144735-BE7DCCA3-BCC9-446B-9011-F7C5F4C32C0AQ58553813-5973FBCF-43E3-49F1-AE43-27597683E798
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@ast
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@en
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@nl
type
label
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@ast
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@en
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@nl
prefLabel
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@ast
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@en
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@nl
P2860
P1476
Ten years of Orthoclone OKT3 (muromonab-CD3): a review
@en
P2093
P2860
P304
109-19; quiz 120-1
P356
10.7182/PRTR.1.6.3.8145L3U185493182
P407
P577
1996-09-01T00:00:00Z